The claim had to be rejected. The costs in question are incurred during the IP and they concern the production and sale of the product under investigation. In the light of the Salmon panel report the Jindal Group cited, and in accordance with the third sentence of Article 2(5), subparagraph 3 of the basic Regulation, costs shall be adjusted appropriately for those non-recurring items of cost which benefit future and/or current production. The Commission acknowledged that the claimed COVID-19 lockdown related costs are of a non-recurring nature. However, the specific costs incurred during the COVID-19 lockdown are fixed costs only and simply result from an underuse of available and otherwise used capacity. By definition, they cannot benefit future production, such as for instance investment costs could. Neither can they benefit current production since they are rather resulting directly from a one-time force majeure event, the COVID-19 lockdown.
38 3. DUMPING › 3.1. India › 3.1.2. Normal value, Regulation (EU) 2021/2012
In forcesince 17 Nov 2021